Unity Biotechnology, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2023-08-23: Study NCT06011798; Company role Lead sponsor; Phase Phase 2; Status Completed.
- 2022-03-02: Study NCT05275205; Company role Lead sponsor; Phase Phase 2; Status Completed.
- 2021-06-25: Study NCT04857996; Company role Lead sponsor; Phase Phase 2; Status Completed.
- 2020-10-08: Study NCT04537884; Company role Lead sponsor; Phase Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2023-08-23 | NCT06011798 Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE) | Lead sponsor | Phase 2 | Completed Results posted | Diabetic Macular Edema; Retinal Disease; Macular Edema; Diabetes Mellitus; Diabetic Retinopathy; Retinal Degeneration; Retinal Diseases; Eye Diseases; Edema | 52 | 2025-04-08 |
| 2022-03-02 | NCT05275205 Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION) | Lead sponsor | Phase 2 | Completed Results posted | Neovascular Age-related Macular Degeneration | 51 | 2023-07-25 |
| 2021-06-25 | NCT04857996 Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD) | Lead sponsor | Phase 2 | Completed Results posted | Diabetic Macular Edema (DME) | 65 | 2023-04-06 |
| 2020-10-08 | NCT04537884 Safety and Tolerability Study of UBX1325 in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration | Lead sponsor | Phase 1 | Completed | Diabetic Macular Edema; Neovascular Age-related Macular Degeneration | 19 | 2022-01-25 |
| 2020-04-20 | NCT04349956 Long-Term Follow-Up Study of Patients With Osteoarthritis of the Knee Treated With UBX0101 or Placebo | Lead sponsor | Observational | Terminated | Knee Osteoarthritis | 161 | 2020-11-02 |
| 2020-01-23 | NCT04229225 A Study of Single and Repeat Dose Administration of UBX0101 in Patients With Osteoarthritis of the Knee | Lead sponsor | Phase 1 | Completed | Knee Osteoarthritis | 35 | 2020-09-18 |
| 2019-10-30 | NCT04129944 A Study to Assess the Safety and Efficacy of a Single Dose of UBX0101 in Patients With Osteoarthritis of the Knee | Lead sponsor | Phase 2 | Completed Results posted | Osteoarthritis, Knee | 183 | 2020-08-07 |
| 2018-05-16 | NCT03513016 A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee | Lead sponsor | Phase 1 | Completed | Osteoarthritis, Knee | 78 | 2019-04-12 |
| 2017-03-02 | NCT03100799 An Exploratory Clinical Study to Investigate Biomarkers of Senescence in Patients With Osteoarthritis of the Knee | Lead sponsor | Not applicable | Completed | Osteoarthritis, Knee | 30 | 2017-07-10 |